 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023 Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023 PR Newswire CARMIEL, Israel, July 31, 2023 Company to host conference call and webcast...

Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023

Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results PR Newswire CARMIEL, Israel, Feb. 27, 2023 Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel, Feb. 27...

Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results

Protalix BioTherapeutics to Report Third Quarter 2022 Financial and Business Results on November 14, 2022 Protalix BioTherapeutics to Report Third Quarter 2022 Financial and Business Results on November 14, 2022 PR Newswire CARMIEL, Israel, Nov. 7, 2022 Company to host conference call and webcast...

Protalix BioTherapeutics to Report Third Quarter 2022 Financial and Business Results on November 14, 2022

---
- Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission
  of a Marketing Authorization Application to the European Medicines Agency for PRX-102
  for the Treatment of Fabry Disease Protalix BioTherapeutics and Chiesi Global Rare
  Diseases Announce the Submission of a Marketing...


Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Application to the European Medicines Agency for PRX-102 for the Treatment of Fab

---
- NEW YORK, June 07, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims
  on behalf of investors of Protalix BioTherapeutics, Inc. (Protalix or the Company)
  (NYSE:PLX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com
  or 888-476-6529, ext. 7980. The ...


SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX

---
- 'SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors
  of Protalix BioTherapeutics, Inc. - PLX SHAREHOLDER ALERT: Pomerantz Law Firm Investigates
  Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX PR Newswire
  NEW YORK, June 3, 2021 NEW YORK, June 3, 2021...'


---
- Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA
  Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease Protalix
  BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date
  for Pegunigalsidase Alfa for the Proposed Treatment...


Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

---
- Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase
  III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the
  Treatment of Fabry Disease Protalix BioTherapeutics Announces Positive Topline Results
  from the BRIDGE Phase III Open-Label, Switch-...


Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease

---
- CARMIEL,Israel, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc.(NYSE
  American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development
  and commercialization of recombinant therapeutic proteins including a late-stage
  clinical product expressed through its ...


Protalix BioTherapeutics Receives Listing Deficiency Letter from NYSE American

Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Carmiel, Israel.

Watchers	16,895
52-Wk Low	$1.00
52-Wk High	$3.55

Market Cap	$115.25M
Volume (M)	81,225.00
52-Wk High	$3.55
52-Wk Low	$1.00

PLX Protalix BioTherapeutics Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals